Cancer drug RVU120 gets extended trial for ongoing patients
NCT ID NCT06987058
First seen Jun 26, 2026 · Last updated Jul 29, 2026 · Updated 2 times
Summary
This study offers continued RVU120 treatment to up to 10 patients with advanced solid tumors, acute myeloid leukemia, or high-risk myelodysplastic syndrome who are already benefiting from the drug in an earlier trial. The main goal is to monitor safety and see how long patients can stay on treatment. Participants must have completed at least 5 cycles in the parent study and have no other available options.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- RVU120 (a drug that blocks certain proteins in cancer cells)
- What this could lead to
- If successful, this study could show that long-term RVU120 treatment is safe and helps control advanced solid tumors, AML, or high-risk MDS.
- What could go wrong
- This is a small rollover study (10 people) with no control group, so results may not apply broadly. Side effects are possible, and the drug may stop working over time.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKAEMIA (AML) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Clinica Universidad de Navarra
Pamplona, 31008, Spain
-
Uniwersyteckie Centrum Kliniczne
Gdansk, 80-214, Poland
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can your own immune cells beat advanced cancer?
- Tumor DNA mapping may unlock personalized cancer therapies
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can a pill outsmart Tumors' defenses?
- Can a new immune drug outsmart Hard-to-Treat tumors?
- Can a protein calm the immune System's overreaction to cancer treatment?